US FDA Makes Case For Quality Management Maturity Ratings

High ratings could strengthen company financial performance, agency suggests. But stakeholders would need to understand the difference between site QMM and product quality for the incentives to work properly. More details to follow in upcoming workshop.

Enjoying the benefits of maturity
time to enjoy the benefits of maturity • Source: Alamy

The Office of Pharmaceutical Quality in the US Food and Drug Administration’s Center for Drug Evaluation and Research 8 April laid out its case for rating industry on what the agency calls quality management maturity so that manufacturers will work harder to ensure a stable supply of quality pharmaceuticals.

The pitch made in the agency's new white paper on the topic is that high-quality pharmaceutical manufacturers would benefit from recognition and reward, while the people who buy, dispense and use their products would

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Compliance